CPT code 0029U designates a Proprietary Laboratory Analyses (PLA) test: the Focused Pharmacogenomics Panel developed and offered by the Mayo Clinic. As a PLA CPT code, 0029U corresponds to one unique, brand- or lab-specific assay that provides pharmacogenomic information to guide medication selection and dosing. This type of testing is increasingly relevant nationally as precision medicine grows and clinicians seek genetic insights to reduce adverse drug events and optimize therapy.

Key payers included in national coverage discussions are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise outline of the clinical purpose of the test, typical sites where the service is delivered, and the role such PLA codes play in coding and billing workflows. The publication reviews payer coverage themes and benchmarking considerations for PLA pharmacogenomic assays, summarizes common modifier usage patterns, and situates 0029U within the broader trend of proprietary molecular diagnostics entering standard clinical practice.

This summary provides policy and billing stakeholders with the essential context needed to understand what 0029U represents, which payers are commonly addressed in coverage discussions, and what topics—coverage benchmarks, coding implications, and clinical utility—are covered in the full analysis. Data not available in the input is noted where applicable.